As with most professions – especially those that involve longer-term outcomes – the way people get good at BD is with experience. So, I’d like to share some of my experiences doing BD from various vantage points, with the hope that it might help you jump start the career of anyone interested in BD. Or for those not in BD, this may give you a peak behind the curtain for this professional area that is so active and at the intersection of many disciplines in drug development.
This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC.
Read more.
The dreaded “lockup expiry” is something all newly-minted public biotechs begin to worry about shortly after their offerings. The fear seems reasonable: venture investors and other large shareholders, now free to trade, dump large amounts of stock into the market quickly, creating significant downward pressure on stock prices.
Read more.
When I first moved from the UK to the US, I told my parents that there was more biotech VC investment in Cambridge, MA each quarter than there was in the whole of the UK in a year. Since then, my mother has been cutting ‘biotech is booming’ articles out of British newspapers to tempt me ‘home’. This stack of press clippings reflects the UK’s intention to become the ‘third global biotech cluster,’ which highlights the reality that aside from the top two clusters in Boston and San Francisco, the US looks a lot like Europe (as discussed by Bruce Booth in ‘The Inescapable Gravity of Biotech’s Key Clusters’). The heat of the biotech ecosystem in these coastal cities is gathering talent, science and investment from cooler areas (including overseas) in a twister phenomenon that currently shows no signs of abating. However, just as the global weather pattern is changing, climate change indicators are visible on the horizon in biotech.
This post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Read more.
A couple of veteran drug developers are guiding a stealthy startup dubbed Akrevia Therapeutics out into the open today after a pair of high-profile biotech investors blessed the operation with a $30 million launch round.
Read more.
The biotech IPO market continues to march forward, with five new offerings expected to price in the next week or so. Investor demand for stories advancing novel innovative therapies remains at historic levels – extending what is now over a six-year window for biotech IPOs.
Read more.